This profile was last updated on 5/15/2014 and contains contributions from the  Zoominfo Community.
is this you? Claim your profile.
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and liga... more.
The Freeman Lab
Martin H. Hager, Ph.D. (2006-2009)
The Freeman Lab
Martin H. Hager, M.Sc., Ph.D. DOD PCRP Fellow Staff Scientist Galm, U., Hager, M.H., vanLanen, S.G., Ju, J., Thorson, J.S., and Shen, B. (2005) Antitumor Antibiotics: Bleomycin, Enediynes, Mitomycin. Chem. Rev. 105: 739-758. Singh, S., Hager, M.H., Zhang, C., Griffith, B.R., Lee, M., Hallenga, K., Markley, J.R., and Thorson, J.S. (2006) Structural insight into self-sacrifice mechanism of enediyne resistance. ACS Chem. Biol. 1 (7), 451- 460. Hager, M.H., Solomon, K.R., and Freeman, M.R. (2006) The role of cholesterol in prostate cancer. Mukhopadhyay, N.K., Kim, J., Cinar, B., Ramachan, A., Hager, M.H., Adam, R.M., Raychaudruri, P., DeBenedetti, A., and Freeman, M.R. (2009) Heterogeneous Nuclear Ribonucleoprotein K is a Novel Regulator of Androgen Receptor Translation. Cancer Res. 69 (6): 2210-2218. Di Vizio, D., Kim, J., Hager, M.H., Morello, M., Rubin, M.A., Adam, R.M., Yang, W., and Freeman, M.R. (2009) Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease. Cancer Res. 69 (13): 5601-5609